Literature DB >> 27796405

[Prognostic assessment in private healthcare insurance part 1 : Risk of osteoarthritis].

H-T Klemm1, A Naumann2, G Hofmann3,4, G Spahn3,5.   

Abstract

After examining the cause of an accident the medical expert working in the area of private health care insurance under the general accident insurance (AUB) sample conditions must ascertain incapacity within a period of time that has been contractually agreed upon between the parties involved. In addition, this person must also state their position on the question as to whether there may exist any circumstances up to the latest possible point in time in insurance terms that would comprise an adequate prognosis of a future change in the long-term condition. This requires a high probability.The sole risk of the evolution of the functional deficit arising from a proven or prognosticated post-traumatic osteoarthritis is excluded from this standard of proof which means that flat-rate risk supplements are not suited to this individualized approach and thus do not apply.

Entities:  

Keywords:  Incapacity; Osteoarthritis; Private healthcare insurance; Prognosis; Risk of osteoarthritis

Mesh:

Year:  2016        PMID: 27796405     DOI: 10.1007/s00113-016-0272-3

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  3 in total

Review 1.  [The time-related risk for knee osteoarthritis after ACL injury. Results from a systematic review].

Authors:  G Spahn; M Schiltenwolf; B Hartmann; J Grifka; G O Hofmann; H-T Klemm
Journal:  Orthopade       Date:  2016-01       Impact factor: 1.087

2.  The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study.

Authors:  D T Felson; A Naimark; J Anderson; L Kazis; W Castelli; R F Meenan
Journal:  Arthritis Rheum       Date:  1987-08

Review 3.  Burden of major musculoskeletal conditions.

Authors:  Anthony D Woolf; Bruce Pfleger
Journal:  Bull World Health Organ       Date:  2003-11-14       Impact factor: 9.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.